GeneDx East Completes Nearly RMB 100 Million Series B+ Financing to Advance Big Data-Driven Precision Diagnosis of Genetic Diseases

VCBeat has learned that Joy Orient, a leading Chinese enterprise in precision medicine big data technology, announced today the completion of its nearly RMB 100 million Series B+ financing round. The round was led by existing investor Feitu Venture Capital, with Fenglin Capital participating as a co-investor. Earlier this year, Joy Orient completed a Series B financing round of over RMB 100 million, which was led by Bencao Capital and participated in by Feitu Venture Capital and Yijing Capital.

This financing round will further support Joy Orient in solidifying its leading position in the field of big data-driven precision diagnosis for genetic disorders. With over a decade of deep expertise in precision diagnostic technologies, the company has pioneered the application of medical exome sequencing, whole-exome sequencing (WES), whole-genome sequencing (WGS), transcriptome sequencing (RNA-seq), as well as AI and big data interpretation technologies to the diagnosis of genetic diseases. It has also taken the lead in building a gene-phenotype database based on WES/WGS data from hundreds of thousands of individuals and establishing a comprehensive technical system for gene big data-based diagnosis.

Leveraging its robust expertise in technology and big data analytics and mining, Joy Orient has established distinct advantages in genetic disease testing, characterized by being “comprehensive, accurate, fast, and cost-effective,” and has contributed to multiple scientific discoveries that have unveiled novel disease-causing genes and pathogenic mechanisms.

Joy Orient integrates tumor neoantigen target sequencing, immune repertoire sequencing, and single-cell sequencing, ushering in the era of panoramic sequencing big data for precision oncology NGS. By combining its core technologies—including a cost-effective gene data acquisition system, an AI-powered cloud platform for automated precision diagnostics, and an automated big-data mining platform for scientific research—with a comprehensive portfolio of multidisciplinary precision diagnostic products and services, Joy Orient has created an industry-leading integrated platform. This platform provides hospitals with end-to-end solutions for the acquisition, analysis, and mining of omics big data.

Joy Orient was awarded First Prize in the Beijing Division of the 2019 China Innovation and Entrepreneurship Competition and recognized as one of the 99 Outstanding Enterprises nationwide; it also received Third Prize in the 2020 “Direct to Wuzhen” Global Internet Entrepreneurship Competition. Additionally, Joy Orient was honored as one of the Top 80 Innovative Enterprises in China’s Healthcare and Wellness Sector (2020) by Cyzone, ranked among the Top 20 in the Medical Technology Segment, and listed in the “Top 100 Chinese Innovative Medical Services” in 2021.

Feitu Ventures is an investment institution focused on China's hard technology sector. The fund primarily invests in chips, semiconductor equipment and materials, industrial robotics and advanced manufacturing, precision medicine, medical devices and services, and related fields.

Fenglin Capital adopts the corporate strategy of “focusing on value-added services and committing to long-term mutual success,” striving to become the “most professional and most trustworthy” emerging boutique private equity investment firm. It is dedicated to supporting the sustained and healthy growth of its portfolio companies and committed to delivering superior returns to investors.

Fenglin Capital focuses on investment opportunities in the growth, mature, and M&A restructuring stages. It targets the primary and pre-IPO capital markets, seeking projects with outstanding teams, leading technologies, and high growth potential in sectors such as advanced manufacturing, new energy, new materials, next-generation information technology, biopharmaceuticals, and education and culture. By integrating industry resources and providing professional value-added services, Fenglin Capital empowers enterprise development.

Joy Orient is a leading enterprise in China’s precision diagnostics sector. With over a decade of deep engagement in the industry, it has built a gene-phenotype database comprising hundreds of thousands of Chinese individuals. Leveraging core technologies such as advanced data acquisition systems, an AI-powered cloud platform for automated precision diagnostics, and an automated big-data mining platform for scientific research, along with a comprehensive product and service portfolio spanning multiple disciplines, Joy Orient has emerged as an industry-leading provider of one-stop NGS precision diagnostics laboratory services and integrated big-data solutions.